Clinical efficacy of immunotherapy in allergic rhinitis

Basit Öğe Kaydı
dc.contributor.authorOktemer T.
dc.contributor.authorAltintoprak N.
dc.contributor.authorMuluk N.B.
dc.contributor.authorSenturk M.
dc.contributor.authorKar M.
dc.contributor.authorBafaqeeh S.A.
dc.contributor.authorCingi C.
dc.date.accessioned2020-06-25T15:17:47Z
dc.date.available2020-06-25T15:17:47Z
dc.date.issued2016
dc.departmentKırıkkale Üniversitesi
dc.description.abstractBackground: Aeroallergen immunotherapy (AIT) should be considered for patients who exhibit symptoms of allergic rhinitis (AR), rhinoconjunctivitis, and/or asthma after natural exposure to allergens and who also demonstrate specific immunoglobulin E antibodies against relevant allergens. Methods: In this paper, clinical efficacy of immunotherapy in allergic rhinitis is reviewed. Result: Subcutaneous allergen immunotherapy (SCIT) is effective for seasonal and perennial AR. Sustained effectiveness requires several years of treatment. SCIT may prevent the development of allergic asthma in children with AR. Sublingual allergen immunotherapy (SLIT) is currently considered an alternative treatment to the subcutaneous route. The use of SLIT has been included in international guidelines for the treatment of AR with or without conjunctivitis. Conclusion: Patients treated with SCIT are at risk of both local and systemic adverse reactions; however, in most cases, symptoms are readily reversible if they are recognized early and treated promptly. The safety profile of SLIT is good; therefore, SLIT can be self-administered by patients in their homes. In this article, we reviewed the efficacy and safety of allergen immunotherapy. Copyright © 2016, OceanSide Publications, Inc.en_US
dc.description.sponsorshipKing Saud Universityen_US
dc.description.sponsorshipPreparation of this paper, including design and planning, was supported by the Continuous Education and Scientific Research Association. The authors extend their appreciation to the International Scientific Partnership Program (ISPP) at King Saud University for funding this research work through ISPP# 0041 The authors have no conflicts of interest to declare pertaining to this articleen_US
dc.identifier.doi10.2500/ajra.2016.30.4368
dc.identifier.endpageS7en_US
dc.identifier.issn19458924
dc.identifier.issue5en_US
dc.identifier.pmid27658025
dc.identifier.scopus2-s2.0-85014118974
dc.identifier.scopusqualityQ1
dc.identifier.startpageS4en_US
dc.identifier.urihttps://doi.org/10.2500/ajra.2016.30.4368
dc.identifier.urihttps://hdl.handle.net/20.500.12587/2524
dc.identifier.volume30en_US
dc.identifier.wosWOS:000729285000002
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherOceanSide Publications Inc.en_US
dc.relation.ispartofAmerican Journal of Rhinology and Allergy
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleClinical efficacy of immunotherapy in allergic rhinitisen_US
dc.typeReview Article

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WOS İndeksli Yayınlar Koleksiyonu